My watch list  


Systematic (IUPAC) name
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
CAS number 28395-03-1
ATC code C03CA02
PubChem 2471
DrugBank APRD00294
Chemical data
Formula C17H20N2O5S 
Mol. mass 364.417 g/mol
SMILES search in eMolecules, PubChem
Pharmacokinetic data
Bioavailability almost complete
Protein binding 97%
Metabolism hepatic
Half life 60-90 minutes
Excretion renal
Therapeutic considerations
Pregnancy cat.

B3(AU) C(US)

Legal status

Prescription Only (S4)(AU) POM(UK) -only(US)

Routes oral

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. The main difference between the two substances is in bioavailability. Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Bumetanide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE